Suzuki S et al., 2002: Rat medium-term liver bioassay finding that fenbendazole, although it raised CYP1A2 protein 2.3-fold, did not increase preneoplastic foci when combined with a known carcinogen. It is a negative result against the idea that fenbendazole's enzyme induction drives liver tumour promotion.
These results suggest that elevated CYP1A2 expression is not sufficient to enhance MeIQx-induced hepatocarcinogenesis.
Suzuki S et al., 2002: Rat medium-term liver bioassay finding that fenbendazole, although it raised CYP1A2 protein 2.3-fold, did not increase preneoplastic foci when combined with a known carcinogen. It is a negative result against the idea that fenbendazole's enzyme induction drives liver tumour promotion. Animal study (rat, medium-term liver bioassay, GST-P positive foci endpoint); Japan (Nagoya City University); fenbendazole in the diet with MeIQx, dose not stated in the abstract. Funder: Japanese national research support. Declared conflicts: none recorded. Comparator: MeIQx alone and untreated controls. Bearing CONTRADICTS the strong reading of C2 that fenbendazole's liver findings amount to tumour promotion: the same laboratory tradition that reported tumour-promoting effects elsewhere found no promotion here, and its own conclusion is that CYP1A2 induction is not sufficient. The row still satisfies C2's request to record the liver findings at full strength. Study type: animal.
